<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Preclinical data suggested that, in the presence of human epidermal growth factor receptor (HER)-3-altered activation, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells may escape anti-epidermal growth factor receptor (EGFR)-mediated cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>HER-3 overexpression may then represent a key factor for resistance to anti-EGFR antibodies in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of our analysis was to investigate a possible correlation between HER-3 expression and clinical outcome in <z:mp ids='MP_0002169'>wild-type</z:mp> K-<z:mp ids='MP_0011356'>RAS</z:mp> advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients receiving cetuximab and irinotecan </plain></SENT>
<SENT sid="3" pm="."><plain>We retrospectively analyzed immunoreactivity for HER-3 in <z:mp ids='MP_0002169'>wild-type</z:mp> K-<z:mp ids='MP_0011356'>RAS</z:mp> advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients receiving irinotecan and cetuximab </plain></SENT>
<SENT sid="4" pm="."><plain>Eighty-four advanced <z:mp ids='MP_0002169'>wild-type</z:mp> K-<z:mp ids='MP_0011356'>RAS</z:mp> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients were available for HER-3 analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Forty patients (48%) had a HER-3(-) <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e>, whereas the remaining 44 cases (52%) were deemed HER-3(+) </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with HER-3(-) and HER-3(+) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, we observed a partial response in 17 (42%) and eight (18%) patients respectively; progressive disease occurred in 11 (35%) and 26 (53%) patients with HER-3(-) and HER-3(+) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, respectively (p = .003) </plain></SENT>
<SENT sid="7" pm="."><plain>The median progression-free survival time was 6.3 months in patients with HER-3(-) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and 2.8 months for those who had HER-3-overexpressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (p &lt; .0001) </plain></SENT>
<SENT sid="8" pm="."><plain>The median overall survival time was 13.6 months in patients showing HER-3(-) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and 10.5 months for those who had HER-3-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (p = .01) </plain></SENT>
<SENT sid="9" pm="."><plain>HER-3 proved to be a predictive factor for clinical outcome in <z:mp ids='MP_0002169'>wild-type</z:mp> K-<z:mp ids='MP_0011356'>RAS</z:mp> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients treated with cetuximab </plain></SENT>
<SENT sid="10" pm="."><plain>Combined HER-3 and K-<z:mp ids='MP_0011356'>RAS</z:mp> analysis may represent an effective strategy for better selection of responding <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>